TACS: Ticlopidine and Aspirin Combination for Stroke Researchers continue to investigate approaches to augmenting aspirin as secondary prevention against stroke recurrence -- and the results for ticlopidine may be promising.
Legal Disclaimer
The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the 15th European Stroke Conference. These materials and the related activity are not sanctioned by the 15th European Stroke Conference or the commercial supporter of the conference, and do not constitute an official part of that conference.
The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
